Spur Capital Partners

Spur Capital focuses primarily on early-stage, technology-centric, U.S. venture capital partnerships. We have a successful history of durable relationships with top-tier venture capital firms as well as uncovering up-and-coming firms. Our limited partners are leading private foundations, endowments and institutional investors in the United States and Western Europe.

John Czerwionka

Partner

Joan Heidorn

Managing Director and Co-Founder

Matthew Horten

Managing Director

C. Bradford Kelly

Managing Director and Co-Founder

2 past transactions

Neurona Therapeutics

Venture Round in 2025
Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

Neurona Therapeutics

Series E in 2024
Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.